Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Athira Pharma Inc (NQ: ATHA ) 3.340 -0.090 (-2.62%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Athira Pharma Inc < Previous 1 2 3 4 5 6 7 8 9 Next > ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024 August 01, 2024 ATHA stock results show that Athira Pharma beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates August 01, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024 July 31, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease July 09, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients June 12, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS) June 11, 2024 First-in-human, dose escalation study to evaluate safety, tolerability and pharmacokinetics in healthy volunteers with trial completion expected by year-end 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma to Participate in Upcoming June Conferences May 29, 2024 Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer’s Disease on Track for Second Half of 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action May 17, 2024 From Athira Pharma, Inc. Via GlobeNewswire ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024 May 15, 2024 ATHA stock results show that Athira Pharma beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates May 15, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma to Participate in Upcoming May Conferences May 02, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer April 15, 2024 Experienced clinical development leader with a strong track record of advancing therapeutics from early development to approval and commercialization From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease April 11, 2024 Fosgonimeton counteracts mechanisms of amyloid-beta (Aβ)-driven toxicity and demonstrates neuroprotection in preclinical models of Alzheimer’s disease From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting April 03, 2024 Presentation to highlight therapeutic potential of Athira’s small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and... From Athira Pharma, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session March 27, 2024 Via Benzinga Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference March 08, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates February 22, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) February 08, 2024 Results demonstrate ATH-1105 is neuroprotective, preserves motor and nerve function and extends survival in preclinical models of ALS From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update January 08, 2024 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease January 03, 2024 From Athira Pharma, Inc. Via GlobeNewswire $1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying January 02, 2024 The Dow Jones index closed lower by around 20 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... Via Benzinga Topics Stocks Exposures US Equities Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies December 12, 2023 From Athira Pharma, Inc. Via GlobeNewswire Sidoti Events, LLC's Virtual December Small-Cap Conference December 05, 2023 Via ACCESSWIRE These biotechs targeting multiple neurodegenerative diseases December 01, 2023 A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market. Via MarketBeat Athira Pharma to Participate in Sidoti December Small Cap Investor Conference November 29, 2023 Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer’s disease From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND November 28, 2023 Presentation to highlight preclinical data from ATH-1105, Athira’s potential treatment candidate for amyotrophic lateral sclerosis (ALS) From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease November 15, 2023 Data presented at Society for Neuroscience Annual Meeting 2023 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates November 09, 2023 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma to Participate in Jefferies London Healthcare Conference November 08, 2023 From Athira Pharma, Inc. Via GlobeNewswire Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) October 05, 2023 From Athira Pharma, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.